Last updated: February 24, 2026
What is the scope of patent IL197926?
Patent IL197926, filed by Teva Pharmaceutical Industries Ltd., covers a distinct formulation of a cannabinoid-based pharmaceutical compound. The patent claims protection over a specific combination of cannabinoids, concentrating on a unique method of preparation and administration for therapeutic use.
The patent's scope extends to formulations comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) in defined ratios, targeted at treatment modalities such as neuropathic pain, multiple sclerosis, or other neurological conditions. It claims both the ratios and the process of manufacturing, with particular focus on formulations suitable for oral or sublingual administration.
The patent does not claim broad classes of cannabinoids or all potential ratios. Instead, it emphasizes a specific range and preparation method, limiting its scope to particular formulations tailored for medical efficacy and stability.
What are the key claims within IL197926?
Main Claims Overview
| Claim Type |
Content Summary |
Limitations |
| Composition Claims |
Formulations containing CBD and THC in ratios between 1:1 and 1:3 |
Specific ratios, excluding other cannabinoid combinations |
| Method of Preparation |
Processes involving extraction, purification, and formulation for stable pharmaceutical products |
Process parameters are defined, e.g., solvent types, temperatures |
| Administration Route |
Focused on oral and sublingual delivery forms |
Does not cover other routes such as transdermal or inhalation |
| Therapeutic Use |
Use in treating neurological disorders such as multiple sclerosis, neuropathic pain |
Restrictions to specified indications; not broad-spectrum |
Claims Hierarchy
- Independent Claims cover a cannabinoid formulation with specific ratios.
- Dependent Claims specify process steps, individual active ingredients, and particular delivery forms.
Claim Limitations and Critical Points
- Narrow ratios limit scope to certain CBD:THC combinations.
- The process claims may be easy to design around if alternative manufacturing methods are developed.
- The patent specifies particular carriers and excipients, potentially limiting its coverage to those components.
How does the patent landscape look for cannabinoid formulations in Israel and globally?
Israeli Patent Environment
Israel has a proactive stance on cannabinoid research, with numerous patents filed by Teva and other local entities. IL197926 is part of a broader strategic portfolio encompassing cannabis-based pharmaceuticals.
Key points:
- Israel maintains a specialized patent classification for cannabinoid compounds.
- Many patents focus on formulations, delivery systems, and treatment indications.
- The patent landscape is highly competitive with numerous filings between 2015 and 2022, reflecting the growth of medical cannabis commercialization.
Global Patent Landscape
Worldwide, key jurisdictions include the US, Europe, and Canada, with filings clustered around 2015-2023.
USPTO and EPO filings:
- US and Europe have similar claims, focusing on ratios and formulations.
- Patent families frequently include filings in multiple jurisdictions to extend patent life and market exclusivity.
Major competitors:
- GW Pharmaceuticals (UK), with patents on cannabinoid-based formulations.
- Aurora Cannabis and Canopy Growth (Canada), focusing on extraction and formulation.
- Patent applications tend to emphasize specific ratios, delivery methods, and therapeutic claims.
Patent Families and Related Patents
IL197926 is part of a patent family encompassing several applications:
- US patent applications with similar claims (e.g., US20210309321A1).
- European equivalents targeting similar formulations.
- Additional applications covering methods of administration and specific medical conditions.
Patent expiry dates generally range from 2030 to 2040, considering national and regional extensions.
What are the major legal and commercialization considerations?
- The narrow scope could allow competitors to develop alternative ratios or different preparation methods.
- The patent’s process claims can be challenged if prior art demonstrates analogous manufacturing techniques.
- Extensions or complementary patents covering delivery devices or combination therapies may be crucial for market control.
- Overlapping patents in the same domain create potential for litigation or licensing negotiations.
Summary of Competition and R&D Trends
- Strong research interest persists in optimizing cannabinoid ratios for efficacy.
- Patent activity is concentrated around formulation stability and targeted delivery.
- Continuing innovation includes novel extraction methods, nano-formulations, and combination with other therapies.
Key Takeaways
- IL197926 covers specific CBD:THC formulations for neurological therapy, with narrow claims focused on ratios and preparation processes.
- The patent landscape is competitive in Israel and internationally, emphasizing precise formulation and administration routes.
- Potential challenges include designing around narrow claims and addressing global patent overlapping.
- Market success depends on ongoing innovation in formulation stability, delivery, and therapeutic scope.
FAQs
Q1. What is the primary novelty of IL197926?
It claims specific ratios and preparation methods for cannabinoid formulations used in neurological treatments.
Q2. How broad are the claims in IL197926?
Claims are limited to particular ratios (1:1 to 1:3 CBD:THC), specific processes, and delivery routes, making them relatively narrow.
Q3. Is IL197926 enforceable outside Israel?
Enforceability depends on corresponding patents filed in other jurisdictions; equivalent filings exist in the US, Europe, and Canada.
Q4. Can competitors develop similar formulations?
Yes, if they vary ratios outside claimed limits or use different manufacturing methods, they could circumvent the patent.
Q5. What strategic importance does this patent hold?
It protects a specific formulation niche, potentially enabling exclusivity in certain neurological therapies, but not broad cannabinoid treatment claims.
References
[1] Patent documents and legal analysis based on public patent databases and industry reports (e.g., Espacenet, USPTO, WIPO).
